On a relative basis, the stock has outperformed the S&P 500 by 3.04% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.96% in the last 1 week, and is up 7.54% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.01% and the 50-Day Moving Average is 5.43%.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $77.11 on Friday but the bulls could not build on the opening and the stock topped out at $77.12 for the day. The stock traded down to $75.08 during the day, due to lack of any buying support eventually closed down at $76.00 with a loss of -1.00% for the day. The stock had closed at $76.77 on the previous day. The total traded volume was 7,523,623 shares.
The company Insiders own 0.24% of Bristol-Myers Squibb Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.74% . Institutional Investors own 74.61% of Bristol-Myers Squibb Company shares. During last six month period, the net percent change held by insiders has seen a change of -16.82%. In a related news, The director, of Bristol Myers Squibb Co, Andreotti Lamberto had unloaded 23,200 shares at $74.65 per share in a transaction on July 7, 2016. The total value of transaction was $1,731,880. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.